HighTower Advisors
GPCR icon

HighTower Advisors’s Structure Therapeutics GPCR Stock Holding History

HighTower Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$464K Buy
9,620
+300
+3% +$20.5K ﹤0.01% 2791
2025
Q4 		$648K Buy
9,320
+320
+4% +$13.1K ﹤0.01% 2435
2025
Q3 		$252K Buy
+9,000
New +$179K ﹤0.01% 3186

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

HighTower Advisors's GPCR Position: Q1 2026 in Review

HighTower Advisors increased its Structure Therapeutics (GPCR) stake by 3.2% in Q1 2026, buying an estimated $20.5K and bringing the position to 9,620 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

HighTower Advisors first reported a position in GPCR in Q3 2025 and has held it in 3 quarters since. The position peaked at $648K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • HighTower Advisors held 9,620 shares of Structure Therapeutics worth $464K as of Q1 2026.
  • HighTower Advisors bought 300 Structure Therapeutics shares in Q1 2026, an estimated $20.5K.
  • Structure Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2791 holding.
  • HighTower Advisors first reported a position in Structure Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • HighTower Advisors's Structure Therapeutics position peaked at $648K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.